Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Caring for Patients With Cancer in the Face of Self-Vulnerability During the COVID-19 Pandemic

Caring for Patients With Cancer in the Face of Self-Vulnerability During the COVID-19 Pandemic Letters 3. Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph who benefit meaningfully from complete consolidation with node dissection for clinically recurrent prostate cancer: results of a just MDT alone. Thus, it is important to perform research single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67 that seeks to identify and inform about all these different (2):299-309. doi:10.1016/j.eururo.2014.02.011 oligoCSPC risk groups. 4. European Association of Urology. Prostate cancer. Accessed July 17, 2020. In conclusion, the meaning of the “all that glitters is not https://uroweb.org/guideline/prostate-cancer/ gold” allegory is that constructs of substance are not a matter 5. Davis ID, Martin AJ, Stockler MR, et al; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. of superficial golden appearance, but are in fact made of Enzalutamide with standard first-line therapy in metastatic prostate cancer. far more mundane, resolute metal. Similarly, we view the N Engl J Med. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835 ORIOLE trial not as the golden finial atop the edifice of MDT, but a piece of the iron foundation upon which subsequent All that glitters is not gold; phase 3 MDT trials are built. Often have you heard http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Caring for Patients With Cancer in the Face of Self-Vulnerability During the COVID-19 Pandemic

JAMA Oncology , Volume 6 (10) – Oct 27, 2020

Loading next page...
 
/lp/american-medical-association/caring-for-patients-with-cancer-in-the-face-of-self-vulnerability-L0s9Pu9DEs

References (6)

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.3330
Publisher site
See Article on Publisher Site

Abstract

Letters 3. Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph who benefit meaningfully from complete consolidation with node dissection for clinically recurrent prostate cancer: results of a just MDT alone. Thus, it is important to perform research single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67 that seeks to identify and inform about all these different (2):299-309. doi:10.1016/j.eururo.2014.02.011 oligoCSPC risk groups. 4. European Association of Urology. Prostate cancer. Accessed July 17, 2020. In conclusion, the meaning of the “all that glitters is not https://uroweb.org/guideline/prostate-cancer/ gold” allegory is that constructs of substance are not a matter 5. Davis ID, Martin AJ, Stockler MR, et al; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. of superficial golden appearance, but are in fact made of Enzalutamide with standard first-line therapy in metastatic prostate cancer. far more mundane, resolute metal. Similarly, we view the N Engl J Med. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835 ORIOLE trial not as the golden finial atop the edifice of MDT, but a piece of the iron foundation upon which subsequent All that glitters is not gold; phase 3 MDT trials are built. Often have you heard

Journal

JAMA OncologyAmerican Medical Association

Published: Oct 27, 2020

There are no references for this article.